Immunogenicity of human papillomavirus recombinant vaccine in children with CKD

Delphine R. Nelson, Alicia M. Neu, Alison Abraham, Sandra Amaral, Donald Batisky, Jeffrey J. Fadrowski

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Background and objectives There is a disproportionate burden of human papillomavirus (HPV) –related genital tract disease in patients with CKD and kidney transplantation; therefore, the potential effect of the quadrivalent HPV vaccine (Gardasil; Merck GmbH, Darmstadt, Germany) is profound. Immune abnormalities associated with CKD and immunosuppression may prevent optimal vaccine response. Our objective was to determine antibody response to the HPV vaccine in adolescent girls with CKD. Design, setting, participants, & measurements This cohort study conducted from 2008 to 2012 included 57 girls aged 9–21 years old with CKD (n=25), on dialysis (n=9), or with status postkidney transplantation (n=23) who received the standard three–dose vaccine series of the HPV vaccine recruited from two pediatric nephrology clinics. Antibody levels to HPV genotypes 6, 11, 16, and 18 were measured before vaccine dose 1 (baseline), <12 months after vaccine dose 3 (blood draw 2), and ≥12 months after vaccine dose 3 (blood draw 3). Seropositivity was defined as antibody level above an established threshold for each HPV genotype. Not all participants completed three blood draws. Results Antibody response to all four HPV genotypes was 100% in the CKD and dialysis groups with samples drawn at <12 and ≥12 months after dose 3 of the HPV vaccine. Among patients with transplants, the percentages of patients achieving seropositivity were significantly lower at blood draw 2 for HPV genotypes 6 (63.6%; P=0.003), 11 (63.6%; P=0.003), and 18 (72.7%; P=0.02) and blood draw 3 for HPV genotypes 6 (62.5%; P=0.02), 11 (50%; P=0.001), 16 (75%; P=0.04), and 18 (50%; P=0.001). Conclusions Antibody response to the quadrivalent recombinant HPV vaccine was robust and sustained in girls and young women with CKD and on dialysis. A less robust response to the vaccine was observed among those with a kidney transplant. Additional study is needed to determine if vaccination before kidney transplantation or an alternative vaccination regimen would benefit transplant recipients.

Original languageEnglish (US)
Pages (from-to)776-784
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Issue number5
StatePublished - 2016


  • Antibody formation
  • Child
  • Chronic kidney disease
  • Clinical immunology
  • Humans
  • Immunosuppression
  • Kidney transplantation
  • Papillomavirus infections
  • Papillomavirus vaccines
  • Renal dialysis

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation


Dive into the research topics of 'Immunogenicity of human papillomavirus recombinant vaccine in children with CKD'. Together they form a unique fingerprint.

Cite this